Vaxart (OTCMKTS:VXRT) Stock Passes Below 200-Day Moving Average – Here’s Why

Shares of Vaxart, Inc. (OTCMKTS:VXRT) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.62 and traded as low as $0.4705. Vaxart shares last traded at $0.4940, with a volume of 547,262 shares trading hands.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Vaxart to a “hold” rating in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Vaxart currently has an average rating of “Hold”.

Vaxart Stock Up 3.2%

The company has a market capitalization of $124.09 million, a PE ratio of 3.19 and a beta of 1.10. The firm’s 50 day simple moving average is $0.55 and its 200 day simple moving average is $0.62.

Vaxart (OTCMKTS:VXRT) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06. The business had revenue of $27.18 million for the quarter, compared to the consensus estimate of $26.21 million. Vaxart had a net margin of 15.88% and a return on equity of 53.04%. As a group, sell-side analysts predict that Vaxart, Inc. will post -0.68 EPS for the current fiscal year.

Institutional Trading of Vaxart

Several institutional investors have recently added to or reduced their stakes in VXRT. Raymond James Financial Inc. lifted its holdings in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 34,075 shares in the last quarter. Invesco Ltd. boosted its position in Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 70,568 shares during the period. Creative Planning bought a new position in Vaxart in the 2nd quarter worth about $33,000. Goldman Sachs Group Inc. bought a new position in Vaxart in the 1st quarter worth about $31,000. Finally, Jones Financial Companies Lllp increased its position in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 478,111 shares during the period. Institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.